Novartis's acquisition of Kate Therapeutics gives it a pipeline of gene therapies for three genetic neuromuscular diseases.

Don't Miss out on Research Tools: Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a late-stage biotechnology company dedicated to developing genetic therapies for rare disorders, with a focus on ...

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

Autism-linked SHANK3 gene mutations disrupt not only neurons but also oligodendrocytes, essential for producing myelin, which ...

The FDA has granted fast-track approval for a groundbreaking gene therapy indicated for a rare genetic disorder called ...

Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or stabilize the ...

In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...

Researchers at Children's Hospital of Philadelphia (CHOP) announced encouraging results from the first ever gene therapy ...

Nov 11 (Reuters) - Genetic testing firm 23andMe ME.O said on Monday it is reducing about 40%, or 200 employees, from its ...

A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma, one of the ...